New hope for tough blood cancers: experimental combo targets leukemia survival
NCT ID NCT03214562
Summary
This study is testing whether adding a newer drug called venetoclax to a standard, strong chemotherapy regimen works better for adults with acute myeloid leukemia (AML). The goal is to see if this combination is safe, find the best dose, and measure how well it controls the cancer in patients who are newly diagnosed or whose cancer has returned or resisted prior treatment. Researchers will track how patients respond and how long the benefits last.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.